TriLink BioTechnologies Announces Supply Agreement with Osmetech Molecular Diagnostics
News May 19, 2009
TriLink BioTechnologies, Inc. has announced that it has signed a service agreement with Osmetech Molecular Diagnostics to supply reagents for Osmetech's recently launched eSensor® Cystic Fibrosis Carrier Detection (CFCD) System and the eSensor® XT-8 System for Warfarin sensitivity.
As part of the agreement, TriLink is providing Osmetech with custom oligonucleotides, which are required reagents for the eSensor® detection systems.
"TriLink provides high quality reagents which have contributed to the excellent performance of our eSensor® products in the marketplace to date," said Osmetech Molecular Diagnostics COO, Pankaj Singhal.
"TriLink is proud to work with Osmetech in the advancement of this important science and rapidly developing commercial opportunity," said TriLink CEO, Dr. Richard Hogrefe.
Cell Chimeras Provide Muscular Dystrophy BreakthroughNews
Fusing together healthy cells with those affected by Duchenne Muscular Dystrophy could improve muscle function.READ MORE
Comments | 0 ADD COMMENT
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018